title: Primary malignant bone tumors--recent developments.
abstract: Primary malignant bone tumors are rare sarcomas with an estimated frequency of about 2900 new cases per year; they constitute less than 0.2% of all cancers diagnosed in the United States. The diagnosis and management of these neoplasms require a team approach, which includes orthopaedic surgeons, radiologists, pathologists, and oncologists. With this approach and current treatment modalities, the 5-year survival for the most common malignant bone tumors, osteosarcoma and Ewing sarcoma, are 70% and 60%, respectively. This review will summarize recent developments and advances in molecular pathogenesis of the more common primary malignant bone neoplasms.
authors.affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, Weill College of Medicine of Cornell University, New York, New York 10065, USA. hameedm@mskc.org
authors.forename: Meera
authors.initials: M
authors.lastname: Hameed
authors.forename: Howard
authors.initials: H
authors.lastname: Dorfman
mesh_terms: D001859:Bone Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D002813:Chondrosarcoma / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D002817:Chordoma / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D002869:Chromosome Aberrations; D003131:Combined Modality Therapy; D025202:Molecular Diagnostic Techniques; D012516:Osteosarcoma / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D010348:Patient Care Team; D012512:Sarcoma, Ewing / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D015996:Survival Rate